Literature DB >> 1710661

Calcitonin gene-related peptide stimulates adenylate cyclase and relaxes intracerebral arterioles.

R M Edwards1, E J Stack, W Trizna.   

Abstract

The effects of calcitonin gene-related peptide (CGRP) on lumen diameter and adenylate cyclase activity in isolated intracerebral arterioles were examined. CGRP produced a concentration-dependent relaxation of spontaneous tone developed by the arterioles with an EC50 value of 3.9 x 10(-9) M. Calcitonin, as well as substance P, which is frequently colocalized with CGRP, had no effect on arteriolar tone. CGRP also relaxed arterioles contracted with the thromboxane mimetic, U-44619, yielding an EC50 value of 3 x 10(-9) M. The CGRP fragment, human CGRP(8-37), antagonized CGRP-induced relaxation in a noncompetitive manner. Adenylate cyclase activity in single arterioles was stimulated by CGRP, but not by substance P, in a concentration-dependent fashion. Half maximal stimulation occurred at 8 x 10(-9) M, whereas maximum stimulation (2.5-fold over basal) occurred at 10(-7) M. CGRP(8-37) inhibited CGRP-stimulated adenylate cyclase activity over a concentration range of 10(-9) to 10(-5) M. The results demonstrate that CGRP stimulates adenylate cyclase activity and is a potent vasodilator of small parenchymal cerebral arterioles in vitro and may play an important role in the regulation of cerebral blood flow.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710661

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches.

Authors:  Oliver Summ; Anna P Andreou; Simon Akerman; Peter J Goadsby
Journal:  J Headache Pain       Date:  2010-10-27       Impact factor: 7.277

3.  Luminal ATP-induced contraction of rabbit pulmonary arteries and role of purinoceptors in the regulation of pulmonary arterial pressure.

Authors:  Eun Bok Baek; Hae Young Yoo; Su Jung Park; Hyang Sun Kim; Seong Deok Kim; Yung E Earm; Sung Joan Kim
Journal:  Pflugers Arch       Date:  2008-06-10       Impact factor: 3.657

Review 4.  [Neuropeptide effects on the trigeminal system: pathophysiology and clinical significance for migraine].

Authors:  K Messlinger; M J M Fischer; J K Lennerz
Journal:  Schmerz       Date:  2011-08       Impact factor: 1.107

5.  Innervation of the dura mater encephali of cat and rat: ultrastructure and calcitonin gene-related peptide-like and substance P-like immunoreactivity.

Authors:  K Messlinger; U Hanesch; M Baumgärtel; B Trost; R F Schmidt
Journal:  Anat Embryol (Berl)       Date:  1993-09

6.  Involvement of nitric oxide in the modulation of dural arterial blood flow in the rat.

Authors:  K Messlinger; A Suzuki; M Pawlak; A Zehnter; R F Schmidt
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 7.  Neurogenic inflammation and its role in migraine.

Authors:  Roshni Ramachandran
Journal:  Semin Immunopathol       Date:  2018-03-22       Impact factor: 9.623

Review 8.  Ryanodine receptors, calcium signaling, and regulation of vascular tone in the cerebral parenchymal microcirculation.

Authors:  Fabrice Dabertrand; Mark T Nelson; Joseph E Brayden
Journal:  Microcirculation       Date:  2013-05       Impact factor: 2.628

9.  Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache.

Authors:  M De Felice; F Porreca
Journal:  Cephalalgia       Date:  2009-05-11       Impact factor: 6.292

10.  Calcitonin gene-related peptide activates the K+ channels of vascular smooth muscle cells via adenylate cyclase.

Authors:  H Miyoshi; Y Nakaya
Journal:  Basic Res Cardiol       Date:  1995 Jul-Aug       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.